Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Coeptis Therapeutics Holdings (COEPW) Non-Current Assets (2021 - 2025)

Coeptis Therapeutics Holdings has reported Non-Current Assets over the past 5 years, most recently at $8.8 million for Q4 2025.

  • Quarterly results put Non-Current Assets at $8.8 million for Q4 2025, up 12.04% from a year ago — trailing twelve months through Dec 2025 was $34.3 million (up 70.01% YoY), and the annual figure for FY2025 was $8.8 million, up 12.04%.
  • Non-Current Assets for Q4 2025 was $8.8 million at Coeptis Therapeutics Holdings, up from $8.2 million in the prior quarter.
  • Over the last five years, Non-Current Assets for COEPW hit a ceiling of $75.8 million in Q1 2022 and a floor of $2.2 million in Q2 2024.
  • Median Non-Current Assets over the past 5 years was $8.0 million (2024), compared with a mean of $22.3 million.
  • Biggest five-year swings in Non-Current Assets: tumbled 95.16% in 2023 and later skyrocketed 284.9% in 2025.
  • Coeptis Therapeutics Holdings' Non-Current Assets stood at $4.6 million in 2021, then decreased by 13.35% to $4.0 million in 2022, then fell by 29.0% to $2.8 million in 2023, then soared by 178.49% to $7.9 million in 2024, then rose by 12.04% to $8.8 million in 2025.
  • The last three reported values for Non-Current Assets were $8.8 million (Q4 2025), $8.2 million (Q3 2025), and $8.5 million (Q2 2025) per Business Quant data.